Autor: |
Malidi Ahamadi, Johannes Kast, Po‐Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V. Upreti |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
CPT: pharmacometricssystems pharmacology. |
ISSN: |
2163-8306 |
Popis: |
Talimogene Laherparepvec (T-VEC) is a first in class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery. Biodistribution data from phase 2 study was used to develop a viral kinetics mechanistic model describing the interaction between cytokines like granulocyte-macrophage colony-stimulating factor (GM-CSF), immune system and T-VEC treatment. Our analysis found 1) viral infection rate has great influence on T-VEC treatment efficacy, 2) an increase of T-VEC dose of 10 |
Databáze: |
OpenAIRE |
Externí odkaz: |
|